Please ensure Javascript is enabled for purposes of website accessibility

Why Becton Dickinson Stock Jumped 11% in January

By John Ballard – Updated Apr 19, 2019 at 10:28AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were encouraged by a stellar first-quarter earnings report and a solid outlook for the year ahead.

What happened

Shares of Becton Dickinson (BDX -1.46%) gained 10.7% last month, according to data provided by S&P Global Market Intelligence. After falling with the broader market in late 2018 over concerns about the economy, investors breathed a sigh of relief when the company announced positive preliminary results for its first quarter of fiscal 2019. The company's actual fiscal first-quarter earnings report on Feb. 5 was as solid as expected. 

So what

Becton Dickinson reported solid operating results for the first quarter, with non-GAAP revenue and earnings per share increasing 5.2% and 14.9%, respectively, year over year. The acquisition of C.R. Bard boosted revenue growth on a GAAP basis by 35% year over year.  

Male patient being assisted by female doctor and female nurse

Image source: Getty Images.

Revenue came in at $4.16 billion, higher than the consensus analyst estimate of $4.11 billion. Adjusted earnings per share of $2.70 also beat analyst expectations of $2.62 per share. 

CEO Vincent A. Forlenza said, "We are very pleased with our strong start to fiscal year 2019. As noted in our pre-announcement, results were better than expected across all three segments." He added, "It is evident that the combination of [Becton Dickinson] and C. R. Bard is delivering value to customers, patients and shareholders around the world." 

Check out the latest Becton Dickinson earnings call transcript.

Now what

The C.R. Bard acquisition was completed in late 2017 and significantly expanded Becton Dickinson's reach across several healthcare markets, including vascular, urology, oncology, and surgical specialty products. The inclusion of Bard has helped Becton expand margins and boost adjusted earnings growth to the mid-teens. 

For fiscal 2019, management is calling for adjusted revenue growth of 5% to 6%, and adjusted earnings-per-share growth of 13% to 14%, or $12.05 to $12.15 per share.

John Ballard has no position in any of the stocks mentioned. The Motley Fool recommends Becton Dickinson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Becton, Dickinson and Company Stock Quote
Becton, Dickinson and Company
BDX
$222.83 (-1.46%) $-3.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.